Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 67 clinical trials
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab (PROMISE-US)

The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and …

antiretroviral
  • 0 views
  • 08 Aug, 2022
  • 16 locations
Validation of Drug Assays in Various Biological Matrices

spectrometry (HPLC-MS/MS). The study involves collecting samples of various bodily fluids to quantify antimicrobials, antivirals, oral contraceptives and erectile dysfunction agents. Samples will also be

  • 19 views
  • 26 Jan, 2021
  • 1 location
TAF Real World Study for Universal Effectiveness (TRUE)

HBV, either NA treatment-nave or treatment-experienced, but TAF nave will be enrolled in this study, and they will be treated with TAF, alone or in combination with other HBV antivirals. During 36

hepatitis b e antigen
tenofovir
antiviral drugs
  • 1 views
  • 19 Feb, 2022
  • 5 locations
Stopping Antiviral Treatment in Chronic Hepatitis B

-term antivirals to be able to stop the treatment if favorable factors are not present. Those include low viral load, long enough duration of treatment, and absence of cirrhosis. Some studies have found

cirrhosis
entecavir
hepatitis
antiviral therapy
tenofovir
  • 0 views
  • 16 Oct, 2021
  • 1 location
AntiCMV mol cules Monitoring in Real-life in Stem Cell Recipients

Cytomegalovirus (CMV) is a ubiquitous herpesvirus that represent a major cause of morbidity in haematopoietic stem cell transplants (HSCT) recipients, mostly through reactivation of the recipient's virus. If left untreated, 40 to 80% of patients will develop CMV infection, leading to CMV disease in 30 to 35 % patients, and …

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers (NeoVie)

antivirals (DAAs) have dramatically changed the treatment landscape of HCV with a cure rate of over 95%. In May 2019, French Health Authorities expanded prescription abilities to all physicians treating

liver disease
pibrentasvir
ribonucleic acid
antiviral drugs
glecaprevir
  • 0 views
  • 25 Jul, 2022
  • 27 locations
HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy

efficacy and safety, IFN-free direct acting antivirals (DAAs) have been the mainstay of therapy for HCV. Furthermore, the world health organization (WHO) has set the goal of global HCV elimination by 2030

  • 0 views
  • 05 Mar, 2021
  • 7 locations
Possible Differences in HCC Course Depending on DAA Treatment

). Liver cirrhosis is considered as one of the most common risk factors of hepatocellular carcinoma (HCC). HCC is seventh most common cancer worldwide. The treatment of HCV with direct-acting antivirals

  • 0 views
  • 25 May, 2022
  • 1 location
The Hepatitis C Transplant Collaborative

In this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.

Accepts healthy volunteers
  • 3 views
  • 23 Mar, 2022
  • 1 location
Breakthrough CMV Lung Transplant -Multicentre

Cytomegalovirus (CMV) infection is the most common opportunistic infection in lung transplantation leading to direct and indirect effects that can result in life threatening complications. The risk of CMV infection is highest when the recipient of the transplant has never been in contact with CMV (negative immunity) and the donor …

  • 0 views
  • 25 Jul, 2022
  • 1 location